Dr Majd Protty
Cardiff Lipidomics Group
- Third Floor of the Sir Geraint Evans Cardiovascular Research Building, Wales Heart Institute, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN
Dr Protty is a WCAT academic clinical registrar in cardiology with an interest in inflammation (bodily reaction to damaging irritants), thrombosis and haemostasis (clot formation in health and disease), as it relates to patients suffering from heart disease.
He is currently enrolled as a PhD student in the Cardiff Lipidomics Group funded by the Wellcome Trust GW4CAT fellowship. His project seeks to investigate the role that inflammatory procoagulant phospholipids play in arterial thrombosis (e.g. heart attacks).
Dr Protty's commitment to academic medicine began when he was 18 years old. He deferred his offer to study medicine for three years to work with Dr Mike Tomlinson (Birmingham) in a world-leading cardiovascular sciences laboratory led by British Heart Foundation (BHF) Professor Steve Watson (Birmingham). Within this time, Dr Protty investigated the intricate signalling pathways of platelets and the role they play in thrombotic and bleeding disorders.
Following this, Dr Protty started his medical training at the University of Birmingham during which he continued to pursue research opportunities. This is best exemplified by being awarded a Wellcome Trust Biomedical Vacation Scholarship to carry out research on anti-HIV RNA aptamers at the University of Oxford (Prof William James). Dr Protty graduated the MBChB (clinical medicine) course in 2013 with honours, three distinctions and 15 national and local prizes.
Subsequently, Dr Protty moved to Wales following his appointment to the highly competitive academic foundation programme in Cardiff. During this time, he continued his journey in academic cardiology and was awarded an MSc degree (Cardiff University) in therapeutics with distinction, studying the use of lipid lowering therapy in patients suffering from cardiovascular disease in Wales.
Dr Protty started his specialist cardiology training after being appointed to the Wales Clinical Academic Track (WCAT) scheme in 2015. During this scheme, Dr Protty developed links with the Cardiff Lipidomics group (Prof Valerie O'Donnell/Prof Peter Collins) and successfully applied to the Wellcome Trust GW4CAT scheme to start his PhD in 2018.
Honours and awards
- 2017 Highest Ranking Abstract in ACS category, British Cardiovascular Society Annual Conference
- 2017 W T Edwards Research Prize, Cardiff Medical Society, Apr 2017
- 2017 Young Investigator Award, International Liver Congress 2017, EASL
- 2013 Chancellor’s Prize winner – this highly prestigious prize is awarded annually to a mature student whose academic progress and performance throughout the course have been outstanding and who has also made an outstanding contribution to the general life of the University as a whole, University of Birmingham.
- 2013 BPS Undergraduate prize in Clinical Pharmacology, British Pharmacological Society
- 2013 Arthur Foxwell Memorial Prize in Medicine winner – awarded to the highest scoring student in Clinical Medicine, University of Birmingham
- 2013 The Medical Society Cup, University of Birmingham
- 2012 British Medical and Dental Students Trust (BMDST) Elective Travel Scholarship
- 2012 Arthur Thomson Trust Elective Travel Scholarship, University of Birmingham
- 2011 First Prize for the Leith Neumann prize in Pathological studies, University of Birmingham
- 2011 Prize for best oral presentation in the immunology session at the LIMSC International Conference, Leiden University, NL
- 2010 The Wellcome Trust Biomedical Vacation Scholarship, to fund a research project at the University of Oxford.
- British Cardiovascular Society (BCS)
- British Society of Echocardiography (BSE) - Full accreditation in transthoracic echocardiography
- British Cardiovascular Intervention Society (BCIS) - Fellow editor
- British Medical Association (BMA)
- General Medical Council (GMC)
- Member of the Royal College of Physicians (MRCP London)
- Member of the Academy of Medical Educators (MAcadMEd)
Committees and reviewing
- Member of the BMA Medical Academic Staff Committee (MASC), 2019-
- Journal Reviewer - Journal of the American College of Cardiology (JACC), 2019
- Grant Reviewer - Wellcome ISSF3, Cardiff University 2018
- Journal Reviewer - European Heart Journal Quality of Care and Clinical Outcomes (EHJ QCCO), 2018
- Education committee for physician trainees, Aneurin Bevan University Health Board 2015-2017
- Mentor/Supervisor for Focused Intensive Care Echocardiography (FICE) (2018-)
- Advanced Life Support (ALS) Instructor, Resus Council (UK) (2017-)
- Associate College (RCP) Tutor, Aneurin Bevan University Healthboard (2015-17)
- Member of the Question Writing Group (Year 1/2) and Exam Scrutiny Board (Year 3), Cardiff University (2013-14)
Cardiovascular (heart) disease is the number one cause of death in the UK. Patients with heart disease who experience a heart attack are at a higher risk of suffering another heart attack, stroke or death. Heart attacks happen as a result of blockages in heart arteries. These blockages are caused by inflammation (a reaction to a damaging irritant) and lead to activation of blood cells such as white cells (responsible for wound healing) and platelets (responsible for blood clotting) which in turn lead to abnormal clotting and blockages in arteries.
Blood clotting happens through interactions of blood proteins with particular fats (phospholipids) that are present on the surface of blood cells and are linked to inflammation. Their potential role in driving abnormal clotting events in heart attacks is unknown. If identified, it may serve as a potential new treatment. This is important since one in ten patients who experience a heart attack remain at risk of developing another heart attack, a stroke, or dying despite current treatment.
During my PhD, I will characterize the phospholipid profile generated by blood cells and components in patients with heart disease, with the aim of identifying the drivers of clotting in these patients, and new treatment targets.